Retatrutide has become one of the most searched medication names online, with claims ranging from dramatic weight loss to benefits for autoimmune disease and even cancer. Here’s where the research actually stands.
What retatrutide is
Retatrutide is an investigational once-weekly injection developed by Eli Lilly. It acts on three hormone receptors involved in appetite and metabolism: GLP-1, GIP, and glucagon. Approved medications like semaglutide target one of these, and tirzepatide targets two.
Is it FDA-approved?
No. As of September 2026, retatrutide is not FDA-approved for any use. Eli Lilly has said it plans to submit an FDA application in early 2027. Until then, the only legitimate access is through clinical trials or the manufacturer’s expanded access program.
Products sold online as “retatrutide,” often labeled “for research use only,” are not approved for human use, and their content, purity, and dose can’t be verified.
What the research shows
Weight and metabolic health
- A phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023) reported average weight loss of about 24% at 48 weeks at the highest dose.
- In 2026, Lilly reported phase 3 results showing weight loss approaching 30% at 80 weeks at the highest dose. Full peer-reviewed publication of the phase 3 program is still underway.
- Large trials in type 2 diabetes, cardiovascular disease, and kidney outcomes are ongoing.
Autoimmune disease
There are no published clinical trials of retatrutide for autoimmune conditions. Research on the broader GLP-1 medication class suggests possible effects on inflammation, but that hasn’t been tested with retatrutide in autoimmune disease.
Cancer
There are no clinical trials of retatrutide as a cancer treatment. Some observational research on GLP-1–based medications and cancer risk exists, but it doesn’t establish that these drugs treat or prevent cancer.
Known side effects and cautions
- Gastrointestinal effects such as nausea, vomiting, diarrhea, and constipation were the most common side effects in trials.
- Heart rate increases were observed in trials.
- Class cautions: approved medications in this family carry warnings about certain thyroid tumors, pancreatitis, gallbladder problems, and use in pregnancy. Retatrutide’s full safety profile will be defined by its phase 3 data.
- Unapproved products carry added risks from unknown content and dosing errors.
The bottom line
Retatrutide shows striking weight-loss results in clinical trials and may become an important obesity medication. It is not approved, it has not been studied for autoimmune disease or cancer treatment, and products sold outside trials are unapproved and unverified.
If you’re interested in medications in this class, talk with a prescriber about FDA-approved options or clinical trial eligibility.
Frequently asked questions
Can I get retatrutide legally?
Only through a clinical trial or the manufacturer’s expanded access program until it’s approved.
Does retatrutide help autoimmune disease?
It hasn’t been studied in autoimmune disease.
Does retatrutide treat cancer?
No. There is no clinical trial evidence that it treats cancer.
Are “research peptide” versions safe?
They’re unapproved for human use, and their contents can’t be verified.
This article is an educational review of published research and regulatory information. It is not a recommendation for any medication and is not a substitute for individual evaluation. From Venturis Clinic in Oklahoma City.
By Alvin Philipose, DC, ICCP
Sources
- Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine. 2023;389:514–526.
- ClinicalTrials.gov. Retatrutide (LY3437943) study records, including TRIUMPH and TRANSCEND programs.
- BioPharma Dive. Lilly to seek FDA approval of obesity drug retatrutide. July 2026.
